Edgewise Therapeutics

• locale

  United States

• market

  STOCKS

• industry

  Biotechnology

• website

  edgewisetx.com

• ipo date

  Mar 26, 2021

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. ...Show More